INSM · INSMED Inc
Market Cap
$27.07B
Shares
218.38M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$120.00
Open$123.89
Day$119.32–124.11
52W close$91.88–211.41
Avg vol 30d2.1M
Short int11.4M · 5.2% float · 6.9d
Short vol70%
Last earningsAug 6, 2026
DataJan 2020–Sep 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 2, 2026
Est · unconfirmed
· in 6 wks
filed Aug 6, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
-17.7%
Trailing year
Short interest
5.2%
Latest settlement · 6.9 days to cover
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Neutral
Momentum
Very Weak
Sentiment
Bearish
Fundamentals
Poor
Quant / Vol
Very High
Market backdrop
VIX 14.8 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−13%
below
Price vs 50-day avg
+1%
above
RSI (14)
46
neutral
MACD trend
Negative
52-week position
24%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−4%
trailing
6-month return
−17%
trailing
YTD return
−31%
this year
Relative strength
−38%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $118 › 200d $137 — 200d above 50d
Institutional flow
Distributing
-2% holders QoQ · +114 funds added
Insider flow
Distributing
Net -$35.7M over 90 days · 100% sells
Short interest
Rising
5.24% of float · ▲ +5.0% MoM · 6.9 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr high
669 holders — near 3-yr high, broad support
Squeeze score
73
high risk · 0–100
Fundamentals
EPS growth
−15%
Y/Y
Free cash flow
$-967.6M
Balance sheet
$36.3M
net debt
Quant / Vol
risk profile
Volatility
62%
annualized · 1-yr
Max drawdown
−57%
past year
ATR
4.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 6, 2026
full-year 2026
BRINSUPRI revenues
Initiated
$1.25B – $1.4B
ARIKAYCE revenues
Initiated
$450M – $470M
peak
BRINSUPRI peak revenue estimate
at least $7B
TPIP peak revenue estimate
at least $6B
ARIKAYCE peak revenue estimate
at least $1B
Full-Year 2026
BRINSUPRI Revenue
Initiated
$1.25B – $1.4B
ARIKAYCE Revenue
Initiated
$450M – $470M
Prior guidance
period ended
· from the 8-K filed Aug 8, 2024
Global ARIKAYCE revenues
· full-year 2024
$340M – $360M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−13%
Bearish
Price vs 50-day avg
+1%
Bullish
RSI (14)
46
Neutral
MACD trend
Negative
Bearish
52-week position
24%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross)
No cross
50d $118 › 200d $137 — 200d above 50d
Institutional flow
Distributing
-2% holders QoQ · +114 funds added
Insider flow
Distributing
Net -$35.7M over 90 days · 100% sells
Short interest
Rising
5.24% of float · ▲ +5.0% MoM · 6.9 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr high
669 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $92
Now $120 · 24%
Range high $211
vs 200-day avg -13%
vs 50-day avg +1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
INSM
this stock
INSMED Inc
|
$27.07B | -31.1% | +66.7% | — | 5.2% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.06B | +12.1% | +46.2% | 29.9 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.80B | +1.7% | +20.8% | 19.4 | 2.5% |
|
MRNA
Moderna, Inc.
|
$61.50B | +422.3% | +4.3% | — | 9.8% |
|
ARGX
Argenx SE
|
$60.93B | +17.8% | — | — | 2.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| INSM | -7.3% | -4.1% | -17.4% | -1.5% | -31.1% |
| SPY | -0.3% | -0.1% | +20.1% | -0.7% | +11.7% |
| vs SPY | -6.9% | -3.9% | -37.5% | -0.8% | -42.8% |
Key facts
CIK
1104506
CUSIP
457669307
13F (30d)
14 filings
11 filers
Visit website
Investor relations